JACC: Heart Failure
Focus Issue: Clinical Trials and Registries
Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart FailureThe DEFEAT-HF Study
Douglas P. Zipes, Petr Neuzil, Heinz Theres, David Caraway, Douglas L. Mann, Clas Mannheimer, Peter Van Buren, Cecilia Linde, Bengt Linderoth, Fred Kueffer, Scott A. Sarazin, Michael J.L. DeJongste and on behalf of the DEFEAT-HF Trial Investigators
Table 1
Table 1
Patient Demographics
| Therapy (n = 42) | Control (n = 24) | Total | p Value | |
|---|---|---|---|---|
| Male | 32 (76.2) | 20 (83.3) | 52 (78.8) | 0.55 |
| Age, yrs | 58 ± 11 | 66 ± 11 | 61 ± 12 | 0.01 |
| Systolic blood pressure, mm Hg | 114 ± 19 | 119 ± 16 | 116 ± 18 | 0.26 |
| Diastolic blood pressure, mm Hg | 70 ± 10 | 70 ± 11 | 70 ± 10 | 0.98 |
| Body mass index, kg/m2 | 31 ± 6 | 29 ± 6 | 30 ± 6 | 0.18 |
| 6-min walk test, m | 309 ± 118 | 352 ± 118 | 324 ± 119 | 0.16 |
| Baseline medications | ||||
| Beta-blocker | 40 (95.2) | 23 (95.8) | 63 (95.5) | 1.00 |
| Diuretic | 40 (95.2) | 22 (91.7) | 62 (93.9) | 0.62 |
| ACE-I or ARB | 38 (90.5) | 22 (91.7) | 60 (90.9) | 1.00 |
| LVEF (Core Lab), % | 29 ± 5 | 29 ± 5 | 29 ± 5 | 0.19 |
| LVEDD (Core Lab), mm | 60 ± 6 | 61 ± 8 | 61 ± 7 | 0.64 |
| LVESVi (Core Lab), ml/m2 | 55 ± 17 | 61 ± 16 | 57 ± 17 | 0.16 |
| Minnesota Living with Heart Failure Questionnaire | 51 ± 20 | 45 ± 18 | 49 ± 19 | 0.20 |
| Heart failure hospitalization 6 months before enrollment | 18 (42.9) | 12 (50.0) | 30 (45.5) | 0.62 |
Values are n (%) or mean ± SD.
ACE-I = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; LVEDD = left ventricular end diastolic dimension; LVEF = left ventricular ejection fraction; LVESVi = left ventricular end systolic volume index.
Advertisement